POINT: Is Chronic Bacterial Infection Clinically Relevant in COPD? Yes

COPD is a complex and heterogeneous disease characterized by chronic airway inflammation.1 The latter may alter airway antimicrobial defense systems and therefore favor the colonization of the bronchial mucosa by potentially pathogenic microorganisms (PPM).2 The most frequent PPMs that are capable of provoking clinical symptoms or that have impact in the COPD prognosis are listed here: Haemophilus influenza and parainfluenza, Streptococcus pneumoniae, Moraxella Catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus and some enterobacteriaceae. These PPMs, and more importantly, the presence of chronic bronchial infection (CBI), which is defined as the repeated isolation of PPMs from the airway overtime, could be a potential mechanism of disease progression and poor health outcomes in patients with COPD.3
Puedes leer el artículo completo aquí: https://journal.chestnet.org/article/S0012-3692(22)01251-X/fulltext
Noticias relacionadas

Human senescent fibroblasts trigger fibrogenic reaction in the lungs of immunodeficient mice
A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as «Aging (Albany NY)» and «Aging-US» by Web of Science) Volume 15, Issue 14, entitled, «Human senescent fibroblasts trigger progressive lung fibrosis in mice.»

COPD and multimorbidity: recognising and addressing a syndemic occurrence
Most patients with chronic obstructive pulmonary disease (COPD) have at least one additional, clinically relevant chronic disease. Those with the most severe airflow obstruction will die from respiratory failure, but most patients with COPD die from non-respiratory disorders, particularly cardiovascular diseases and cancer.

Blood Immunophenotypes of Idiopathic Pulmonary Fibrosis: Relationship with Disease Severity and Progression
The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial.
Más artículos
COPD
- Leonardo M Fabbri et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence
- Singh D, Criner GJ, Agustí A et al. Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
- Alvar Agusti, M.D., Ph.D. – Biologics for COPD — Finally Here
- D. Pellegrino, S. Casas-Recasens, R. Faner, P. Palange, A. Agusti. When GETomics meets aging and exercise in COPD
- Alvar Agustí et al.- GOLD 2023: What’s New, Doc?
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría EPOC en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imagen obtenida en Canva Pro el 18 de mayo de 2023.